The 10th Edition of the Diagnosis and Treatment Guideline for COVID-19 Has Been Released, and Azvudine Tablets Is Once Again the Only Domestic Oral Drug Recommended for the Treatment of COVID-19

On Jan. 6, 2023, the General Office of the National Health Commission and the General Department of the National Administration of Traditional Chinese Medicine released the Diagnosis and Treatment Guideline for COVID-19 (Tentative 10th Edition), and Azvudine Tablets is the only Chinese oral small-molecule drug for the treatment of COVID-19 recommended. It has been covered by the basic medical insurance and included in the basic medical insurance networks of 31 provinces, municipalities, and autonomous regions in China. The price is RMB 270 per bottle.

On Dec. 7, 2022, Azvudine tablets was included in the latest version of Clinical Pharmacy Guideline for Antiviral Treatment of COVID-19 published by Guangdong Pharmaceutical Association.Ten days later, Henan Pharmaceutical Association published the Expert Consensus on the Use of Azvudine for the Treatment of COVID-19. As of now, Azvudine tablets are recommended for antiviral treatment in authoritative treatment protocols, including Shanghai Diagnosis and Treatment Standards for COVID-19 Infections and Graded Diagnosis and Treatment Procedures, Recommendations and Appropriate Technologies for Primary Care of COVID-19 Infections (1st Edition) of Peking Union Medical College Hospital, Diagnosis and Treatment Manual for COVID-19 (Tentative 1st Edition) of the Department of Respiratory and Intensive Care Medicine of West China Hospital of Sichuan University, and Outpatient and Emergency Screening and Treatment Procedures for Adults with COVID-19 Infections of Ruijin Hospital.

Previously, Azvudine tablets was successfully included in the Diagnosis and Treatment Guideline for COVID-19 (9th Edition) on Aug. 9, 2022. Once again, Azvudine tablets is the only domestic oral drug recommended, and are expected to consistently protect people's health.
The original release is as follows:

Notice on the Issuance of the Diagnosis and Treatment Guideline for COVID-19 (Tentative 10th Edition)

General Office of the National Health Commission Medical Emergency Letter [2023] No. 4

To all provinces, autonomous regions, direct-administered municipalities, the Health Commission of Xinjiang Production and Construction Corps, and National Administration of Traditional Chinese Medicine:

Since 2022, the SARS-CoV-2 Omicron has gradually become the overwhelmingly prevalent variant, with significantly increased transmissibility and immune escape capacity, albeit with significantly reduced pathogenicity.

In order to further improve the scientific and standardized diagnosis and treatment of COVID-19 infection, we organized experts to revise the content of the Diagnosis and Treatment Guideline for COVID-19 (9th Edition) and formulated the Diagnosis and Treatment Guideline for COVID-19 (Tentative 10th Edition).
It is hereby issued to you for reference and implementation. 

Attachment: Diagnosis and Treatment Guideline for COVID-19 (Tentative 10th Edition)

Office of National Health Commission
General Department of the National Administration of Traditional Chinese Medicine

Jan. 5, 2023

 
(Form of information disclosure: Active disclosure)

Diagnosis and Treatment Guideline for COVID-19
(Tentative 10th Edition)